top
Please input keywords
Order
*Country
日本
アメリカ
中国
オーストラリア
シンガポール
イギリス
フランス
ドイツ
スイス
イタリア
カナダ
韓国
オランダ
ベルギー
スウェーデン
その他
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hGITR mice
Strain Name C57BL/6-Tnfrsf18tm1(TNFRSF18)/Bcgen Common Name  B-hGITR mice
Background C57BL/6 Catalog number  110012
Related Genes 
TNFRSF18  (tumor necrosis factor receptor superfamily, member 18)

Gene description

TNFRSF18 (GITR) is a type 1 transmembrane protein that can act as a co-stimulatory receptor, expressed increases rapidly on both Tregs and effector T-cells, reaching the highest level on activated Tregs, and also expressed on NK, B, macrophages and dendritic cells. GITR activation can promote effective T-cell function and inhibit Treg function. Preclinical data on GITR-agonist monoclonal antibodies (mAbs) demonstrated antitumour activity and enhancing CD8+ and CD4+ effector T-cell activity and depleting tumour-infiltrating Tregs. Thus representing a potential target to enhance immunotherapy, in particular immune checkpoint inhibitors.


Protein expression analysis

from clipboard


Strain specific GITR expression analysis in homozygous B-hGITR mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hGITR (H/H) mice stimulated with anti-CD3ε in vivo (7.5 μg/mice), and analyzed by flow cytometry with species-specific anti-GITR antibody. Mouse GITR was exclusively detected in WT. Human GITR was exclusively detected in homozygous B-hGITR but not WT mice.


In vivo efficacy of anti-human GITR antibodies


from clipboard


Antitumor activity of anti-human GITR antibodies in B-hGITR mice. (A) Anti-human GITR antibodies inhibited MC38 tumor growth in B-hGITR mice. Murine colon cancer MC38 cells (5ⅹ105) were subcutaneously implanted into heterozygous B-hGITR mice (female, 9 week-old, n=5). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with three anti-human GITR antibodies with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, anti-human GITR antibodies were efficacious in controlling tumor growth in B-hGITR mice, demonstrating that the B-hGITR mice provide a powerful preclinical model for in vivo evaluation of anti-human GITR antibodies. Values are expressed as mean ± SEM